Ayako Suzuki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8054338/publications.pdf

Version: 2024-02-01

185998 138251 5,538 63 28 58 citations h-index g-index papers 67 67 67 7599 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Sex and gender: modifiers of health, disease, and medicine. Lancet, The, 2020, 396, 565-582.	6.3	955
2	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology, 2019, 70, 1457-1469.	3.6	547
3	Drug-induced liver injury. Nature Reviews Disease Primers, 2019, 5, 58.	18.1	409
4	Drug-induced liver injury: Interactions between drug properties and host factors. Journal of Hepatology, 2015, 63, 503-514.	1.8	319
5	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology, 2011, 54, 931-939.	3.6	279
6	No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial. Gastroenterology, 2014, 147, 377-384.e1.	0.6	260
7	Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology, 2014, 59, 471-482.	3.6	256
8	Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology, 2014, 59, 1406-1414.	3.6	250
9	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discovery Today, 2016, 21, 648-653.	3.2	248
10	Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology, 2005, 41, 64-71.	3.6	177
11	Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease Liver International, 2005, 25, 779-786.	1.9	176
12	Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBaseâ,,¢. Drug Safety, 2010, 33, 503-522.	1.4	142
13	A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology, 2016, 64, 85-91.	3.6	128
14	Nonalcoholic Steatohepatitis. Annual Review of Medicine, 2017, 68, 85-98.	5.0	119
15	Nonalcoholic Fatty Liver Disease in Women. Women's Health, 2009, 5, 191-203.	0.7	110
16	Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. Journal of Clinical Medicine, 2020, 9, 1278.	1.0	86
17	Association Between Puberty and Features of Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2012, 10, 786-794.	2.4	74
18	Light to Moderate Alcohol Consumption Is Associated With Lower Frequency of Hypertransaminasemia. American Journal of Gastroenterology, 2007, 102, 1912-1919.	0.2	67

#	Article	IF	Citations
19	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of NonalcoholicÂSteatohepatitis. Clinical Gastroenterology and Hepatology, 2017, 15, 127-131.e2.	2.4	66
20	Hedgehog pathway and pediatric nonalcoholic fatty liver disease. Hepatology, 2013, 57, 1814-1825.	3.6	60
21	Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 1-21.	2.3	58
22	Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver International, 2006, 26, 1209-1216.	1.9	55
23	Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBaseâ,,¢. Regulatory Toxicology and Pharmacology, 2015, 72, 481-490.	1.3	46
24	Age-related differences in reporting of drug-associated liver injury: Data-mining of WHO Safety Report Database. Regulatory Toxicology and Pharmacology, 2014, 70, 519-526.	1.3	45
25	Genetic signatures in choline and $1\hat{a} \in \mathbb{C}$ arbon metabolism are associated with the severity of hepatic steatosis. FASEB Journal, 2013, 27, 1674-1689.	0.2	40
26	Interleukin-15 increases hepatic regenerative activity. Journal of Hepatology, 2006, 45, 410-418.	1.8	37
27	Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men. Clinical Gastroenterology and Hepatology, 2021, 19, 400-402.e2.	2.4	37
28	Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation. Journal of Hepatology, 2022, 77, 1246-1255.	1.8	37
29	Characterizing phenotypes and outcomes of drugâ€associated liver injury using electronic medical record data. Pharmacoepidemiology and Drug Safety, 2013, 22, 190-198.	0.9	32
30	<i>APOL1</i> Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. JAMA Internal Medicine, 2022, 182, 386.	2.6	31
31	Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. Regulatory Toxicology and Pharmacology, 2018, 94, 101-107.	1.3	29
32	Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. Digestive Diseases and Sciences, 2018, 63, 2259-2266.	1.1	26
33	Expression of mitochondrial membrane–linked SAB determines severity of sex-dependent acute liver injury. Journal of Clinical Investigation, 2019, 129, 5278-5293.	3.9	26
34	Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3496-3504.	1.8	25
35	Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD. Clinical Gastroenterology and Hepatology, 2021, 19, 1267-1274.e1.	2.4	25
36	Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Dietâ€Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis. Hepatology, 2021, 74, 3127-3145.	3.6	24

#	Article	IF	CITATIONS
37	Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis. Nature Communications, 2022, 13, 578.	5.8	24
38	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. Journal of Hepatology, 2021, 75, 333-341.	1.8	23
39	Tools for causality assessment in drug-induced liver disease. Current Opinion in Gastroenterology, 2019, 35, 183-190.	1.0	22
40	Regional Anthropometric Measures and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2010, 8, 1062-1069.	2.4	21
41	Associations of gender and a proxy of female menopausal status with histological features of drugâ€induced liver injury. Liver International, 2017, 37, 1723-1730.	1.9	18
42	Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations. Hepatology, 2021, 73, 1199-1206.	3.6	16
43	Nonalcoholic fatty liver disease: does sex matter?. Hepatobiliary Surgery and Nutrition, 2019, 8, 164-166.	0.7	15
44	Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait. JAMA Internal Medicine, $0, , .$	2.6	15
45	Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD. Hepatology Communications, 2021, 5, 598-607.	2.0	12
46	The influence of drug properties and host factors on delayed onset of symptoms in drugâ€induced liver injury. Liver International, 2018, 39, 401-410.	1.9	10
47	Mutational analysis of ATP7B and genotype–phenotype correlation in Japanese with Wilson's disease. Human Mutation, 2000, 15, 454.	1.1	10
48	Oral Tolerance and Pyruvate Dehydrogenase in Patients with Primary Biliary Cirrhosis. Autoimmunity, 2002, 9, 55-61.	0.6	7
49	Drug-Induced Liver Injury. BioMed Research International, 2017, 2017, 1-2.	0.9	7
50	COVID-19-Associated Mortality in US Veterans with and without SARS-CoV-2 Infection. International Journal of Environmental Research and Public Health, 2021, 18, 8486.	1.2	6
51	Serum aminotransferase changes with significant weight loss: sex and age effects. Metabolism: Clinical and Experimental, 2010, 59, 177-185.	1.5	5
52	Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans. Journal of General Internal Medicine, 2022, 37, 4144-4152.	1.3	5
53	A novel phenotypeâ€based drugâ€induced liver injury causality assessment tool (<scp>DILlâ€CAT</scp>) allows for signal confirmation in early drug development. Alimentary Pharmacology and Therapeutics, 2022, 55, 1028-1037.	1.9	4
54	Reproductive Health and Nonalcoholic Fatty Liver Disease in Women: Considerations Across the Reproductive Lifespan. Clinical Liver Disease, 2020, 15, 219-222.	1.0	3

#	Article	IF	CITATIONS
55	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machineÂlearning approach. Archives of Toxicology, 2021, 95, 1793-1803.	1.9	3
56	Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort. Gut, 2022, 71, 1447-1450.	6.1	3
57	Should nonalcoholic fatty liver disease be treated differently in elderly patients?. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 208-209.	1.7	2
58	A Pilot Study: No Therapeutic Effect of L-Alanine in Patients with Nonalcoholic Steatohepatitis. Food and Nutrition Sciences (Print), 2010, 01, 67-73.	0.2	2
59	Statin Therapy Decreases Risk of Hepatic Steatosis and Lobular Inflammation in Patients with Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2010, 105, S116.	0.2	1
60	REPLY:. Hepatology, 2021, 73, 1625-1625.	3.6	0
61	The Association of Serum Thyroid Hormone Levels and Hepatic Gene Expression of Potential Regulators of Intracellular Thyroid Hormone Concentration with Severity of Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2012, 107, S193.	0.2	0
62	Interaction of Vitamin D and Corticosteroid Use in Hospitalized COVID-19 Patients: A Potential Explanation for Inconsistent Findings in the Literature. Current Pharmaceutical Design, 2022, 28, .	0.9	0
63	Abstract 20174: Impact of Entrance Examination on Development of Nonalcoholic Fatty Liver Disease in New University Students. Circulation, 2015, 132, .	1.6	O